Boston Scientific (BSX) Projected to Announce Earnings on Wednesday

Key Points

• Boston Scientific is expected to report Q3 2026 results before the market opens on October 28. Analysts forecast earnings of $0.746 per share and revenue of $5.10 billion, below the company’s guidance of $0.800–$0.820 EPS.
• The company exceeded expectations in its prior quarter, posting $0.86 EPS and $5.44 billion in revenue, with sales up 7.5% year over year.
• Wall Street maintains a “Moderate Buy” consensus with a $68.23 average price target, while insiders—including the CEO—purchased approximately $9.4 million of shares over the past three months.

Boston Scientific (NYSE:BSX - Get Free Report) is projected to issue its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect Boston Scientific to post earnings of $0.7460 per share and revenue of $5.10 billion for the quarter. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Parties can find conference call details on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:00 AM ET.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion for the quarter, compared to analysts' expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The business's revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.75 EPS. On average, analysts expect Boston Scientific to post $3.24 EPS for the current fiscal year and $3.36 EPS for the next fiscal year.

Boston Scientific Price Performance

BSX stock opened at $45.60 on Wednesday. The business has a 50 day simple moving average of $45.84 and a 200-day simple moving average of $49.43. The firm has a market capitalization of $66.08 billion, a PE ratio of 18.46, a price-to-earnings-growth ratio of 1.09 and a beta of 0.58. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific has a 1 year low of $41.38 and a 1 year high of $105.65.

Insider Buying and Selling

In other Boston Scientific news, Director Edward J. Ludwig bought 5,000 shares of Boston Scientific stock in a transaction on Friday, July 31st. The shares were bought at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the transaction, the director directly owned 30,359 shares of the company's stock, valued at $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Michael F. Mahoney purchased 186,240 shares of the firm's stock in a transaction dated Monday, August 3rd. The stock was acquired at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders acquired 194,522 shares of company stock worth $9,385,210. Company insiders own 0.34% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Mizuho set a $55.00 target price on Boston Scientific in a research note on Tuesday, October 13th. Jefferies Financial Group reduced their price target on Boston Scientific from $67.00 to $60.00 and set a "buy" rating on the stock in a report on Thursday, July 30th. Leerink Partners lowered their price target on shares of Boston Scientific from $60.00 to $55.00 in a research report on Friday, October 9th. Canaccord Genuity Group dropped their price objective on shares of Boston Scientific from $70.00 to $66.00 and set a "buy" rating for the company in a report on Thursday, July 30th. Finally, Needham & Company LLC dropped their price objective on shares of Boston Scientific from $77.00 to $57.00 and set a "buy" rating for the company in a report on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $68.23.

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.